Abstract: The present invention relates to a curable isocyanate-free formulation for preparing a polyurethane self-blowing foam comprising at least one multifunctional cyclic carbonate having at least two cyclic carbonate groups at the end of the chain (compound A), at least one multifunctional amine (compound B), water or/and a water source and optionally at least one catalyst (compound D), to a process for preparing said foams and to the thus obtained foams, to a process for recycling the obtained foams and to the thus recycled foams.

Abstract: The present invention relates to a curable isocyanate-free formulation for preparing a polyurethane self-blowing foam comprising at least one multifunctional cyclic carbonate having at least two cyclic carbonate groups at the end of the chain (compound A), at least one multifunctional amine (compound B), at least one masked thiol precursor (compound C) and optionally at least one catalyst (compound D), to a process for preparing said foams, to the thus obtained foams and to the recycling of said foams.

Abstract: The invention provides a complex comprising at least one proteinaceous agent, an ionic polymer comprising a repetitive unit of formula (I): wherein R1 represents a hydrogen atom or a straight or branched chain alkyl group, preferably a straight or branched chain alkyl group comprising from 1 to 6 carbon atoms, for example a methyl group; R2 represents a straight or branched chain alkyl group which is substituted by a group which may have a positive charge at a physiological pH; and optionally a surfactant; a complex for use in a method of medical treatment; a pharmaceutical composition

Abstract: The invention provides a method for synthesizing a compound of formula wherein each R independently represents an optionally substituted aryl, heteroaryl, alkyl, perfluoroalkyl, cycloalkyl, alkoxy, aryloxy, acyl, carboxyl, hydroxyl, halogen, amino, nitro, cyano, sulfo or sulfhydryl group, in ortho, meta or para position to the cycloalkylamine moiety; R1 and R2 each independently represents a hydrogen atom, a lower alkyl group or a cycloalkyl group; R3 represents a hydrogen group, substituted aryl, heteroaryl, alkyl, perfluoroalkyl, cycloalkyl, alkoxy, aryloxy group; Y represents an oxygen atom, a sulfur atom, a NH group, a NR4 group or a CH2 group; R4 represents a hydrogen atom or an alkyl, aryl or a heteroaryl group; and n and m each independently represents an integer from 1 to 5; or a pharmaceutically acceptable salt thereof; or a precursor thereof; wherein the method comprises one or more of the following steps: (a) reacting a compound of formula (II) wherein R, R3, Y, n and m are as defined abo

Abstract: The present invention relates to medical imaging, disease monitoring and theranostic approaches in neoplastic diseases of certain anti-CD38 single-domain antibodies (sdAb).

Abstract: The use of an inhibitor of EXT1 expression and/or activity for the production of a biological entity in a cell. Also, the use of a cell having at least depleted EXT1 expression and/or activity for the production of a biological entity. Further, evidence is provided about the role of glycosylation in rapid dynamism of ER shaping and function. In particular, depletion of EXT1 results in a recomposed ER shaping, which could benefit production of recombinant proteins.

Abstract: A composition comprises: an at least partially hydrolysed polyvinyl acetate component having an hydrolysation degree of at least 5%; a polyalkylene glycol component having a number average molecular mass Mn lower than 9000 g/mol and consisting of one or more substances selected from the group consisting of polyethylene glycol, polypropylene glycol, copolymers of ethylene glycol and propylene glycol, and their derivatives; a positive or negative electrode active component; and a conductive component; wherein the mass ratio between the at least partially hydrolysed polyvinyl acetate component and the positive or negative electrode active component equals at least 0.12 and at most 0.30, and wherein the mass ratio between the polyalkylene glycol component and the positive or negative electrode active component equals at least 0.012 and at most 0.10.

Abstract: Disclosed herein are biomaterial implants, medical devices, or bioprostheses wherein a surface or part thereof is coated with a nanoreservoir comprising a hydrophilic polymer or copolymer backbone crosslinked to a second polymer comprising a hydrophilic backbone and one or more reactive moieties, wherein the nanoreservoir further comprises one or more bioactive molecules, therapeutic molecules, or drugs.

Abstract: The present invention relates to methods for determining the concentration of a carbapenem antibiotic in a biological sample. In particular, the present invention relates to methods for determining the concentration of a carbapenem antibiotic in a biological sample, comprising the steps of: (a) providing a blaOXA-48 class D beta-lactamase (blaOXA-48) or a functionally active variant or fragment thereof; (b) providing a biological sample; (c) contacting the blaOXA-48 or functionally active variant or fragment thereof with the biological sample; and (d) determining the concentration of the carbapenem antibiotic in the biological sample.

Abstract: Pyrimidine derivatives of formula (I): optionally with a detectable isotope, pharmaceutical composition and method of preparation thereof. Pyrimidine derivatives for use in treatment or prevention of bacterial infection in a host mammal in need of such treatment or prevention and use as inhibitors of biofilm formation on a surface of biomaterial or medical device, particularly of cardiovascular device such as prosthetic heart valve or pacemakers. Pyrimidine derivatives for use as radiotracer in diagnosing or prognosing bacterial infection in a host mammal.

Abstract: In vitro methods for diagnosing, prognosing and/or monitoring and treating neutrophilic or eosinophilic airway inflammation in a subject, including determining the amount of one or more volatile organic compounds (VOCs) in exhaled breath from said subject. The invention also provides devices for use in said methods.

Abstract: The present invention refers to osteomodulin (OMD) protein or fragment of osteomodulin (OMD) protein for use in the prognosis and/or diagnosis of osteoarthritis and/or subchondral bone sclerosis of mammals, preferably human individuals. The present invention further refers to a method for prognosis and/or diagnosis of osteoarthritis and/or subchondral bone sclerosis, comprising the following steps: i) measuring osteomodulin (OMD) protein or a fragment or fragments of osteomodulin (OMD) protein in samples of body fluids of mammalian individuals, preferably human serum samples; ii) judging that decreased levels of osteomodulin (OMD) protein or of said fragment(s) compared to levels in body fluids, preferably serum, of healthy individuals indicate onset of osteoarthritis and/or subchondral bone sclerosis.

Abstract: The present invention relates to a curable isocyanate-free formulation for preparing a polyurethane self-blowing foam comprising at least one multifunctional cyclic carbonate having at least two cyclic carbonate groups at the end of the chain (compound A), at least one multifunctional amine (compound B), at least one multifunctional thiol (compound C) and at least one catalyst (compound D), to a process for preparing said foams, to the thus obtained foams and the recycling of said foams.

Abstract: A process to prepare an electrode for an electrochemical storage device by spraying an aqueous slurry composition comprising water, xanthan gum, a source of conducting carbon particles and an active material on an electrode base. The slurry may be made by first mixing solid xanthan gum with the conducting carbon particles and the active material and secondly adding water to the resulting mixture. Alternatively the slurry is obtained by mixing solid xanthan gum with a carbon-based active material and adding water to the resulting mixture obtained.

Abstract: The invention provides a method for synthesizing a compound of formula wherein each R independently represents an optionally substituted aryl, heteroaryl, alkyl, perfluoroalkyl, cycloalkyl, alkoxy, aryloxy, acyl, carboxyl, hydroxyl, halogen, amino, nitro, cyano, sulfo or sulfhydryl group, in ortho, meta or para position to the cycloalkylamine moiety; R1 and R2 each independently represents a hydrogen atom, a lower alkyl group or a cycloalkyl group; R3 represents a hydrogen group, substituted aryl, heteroaryl, alkyl, perfluoroalkyl, cycloalkyl, alkoxy, aryloxy group; Y represents an oxygen atom, a sulfur atom, a NH group, a NR4 group or a CH2 group; R4 represents a hydrogen atom or an alkyl, aryl or a heteroaryl group; and n and m each independently represents an integer from 1 to 5; or a pharmaceutically acceptable salt thereof; or a precursor thereof; wherein the method comprises one or more of the following steps: (a) reacting a compound of formula (II) wherein R, R3, Y, n and m are as defined ab

Abstract: A polyvinyl alcohol has a number-average molecular weight (Mn) from 4,400 to 440,000, a molecular weight distribution (Mw/Mn) from 1.05 to 1.70, a degree of saponification from 80 to 99.99 mol %, wherein the polyvinyl alcohol contains an end group represented by a formula (I) below, and a molar ratio (X) of the end group based on total monomer units and the number-average molecular weight (Mn) satisfy a formula (1) below. Such a polyvinyl alcohol has a narrow molecular weight distribution and a high number-average molecular weight with hue good. (In the formula, R1 denotes an optionally substituted aromatic group having a carbon number from 6 to 20, and R2 denotes a hydrogen atom, an alkyl group having a carbon number from 1 to 20, or an optionally substituted aromatic group having a carbon number from 6 to 20.) X·Mn/44?0.

Abstract: The present invention refers to osteomodulin (OMD) protein or fragment of osteomodulin (OMD) protein for use in the prognosis and/or diagnosis of osteoarthritis and/or subchondral bone sclerosis of mammals, preferably human individuals. The present invention further refers to a method for prognosis and/or diagnosis of osteoarthritis and/or subchondral bone sclerosis, comprising the following steps: i) measuring osteomodulin (OMD) protein or a fragment or fragments of osteomodulin (OMD) protein in samples of body fluids of mammalian individuals, preferably human serum samples; ii) judging that decreased levels of osteomodulin (OMD) protein or of said fragment(s) compared to levels in body fluids, preferably serum, of healthy individuals indicate onset of osteoarthritis and/or subchondral bone sclerosis.

Abstract: The present invention relates to a herbicidal composition comprising at least one phenolic active compound being myricitrin. The invention also relates to the use of such a herbicidal composition.

Abstract: A continuous-flow process for the production of allyl compounds by deoxydehydration of glycerol includes: (a) Forming a reactive solution by mixing glycerol (1) with: a carboxylic acid (2), and/or a triethyl orthoester, preferably triethyl orthoformate (TEOF); (b) Feeding the reactive solution to an inlet of a channel of a thermolysis microreactor module wherein the channel has an inner hydraulic diameter, D=4 A/P, wherein A is the area and P the perimeter of a cross-section of the channel, of not more than 1000 ?m, (c) Exposing the reactive solution to thermolysis by driving a flow of the reactive solution along the channel from the inlet to an outlet, for a thermolysis time, t, at a pressure, P, and at a thermolysis temperature, T, larger than 200° C., to form thermolysis products including at least one allyl compound; and Recovering the thermolysis products at the outlet and separating the at least one allyl compound from the other thermolysis products.

Abstract: An in-vitro method for early diagnosing or prediction of immune-mediated inflammatory diseases, comprising: —obtaining a sample from a subject; —quantifying simultaneously by one LC/MS-MS analysis of said sample, a presence of V65 vitronectin fragment or fragment, variant or degradation product thereof; and a presence of a complement C3f or fragment or variant or degradation products thereof.